Results 101 to 110 of about 1,414 (186)

Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration

, 2020
Purpose. To study the short-term anatomical and functional outcomes in patients with neovascular age-related macular degeneration (nAMD) who were previously treated with conbercept and switched to ranibizumab or bevacizumab due to persistent activity ...
Mengyang Li, Yuou Yao, Jiyang Tang, Jie Hu, Ran Tang, Zhenyu Piao, Jinfeng Qu, Zongyi Wang   +7 more
core   +1 more source

Issue Information

Clinical Case Reports, Volume 13, Issue 10, October 2025.
wiley   +1 more source

Preoperative Intravitreal Conbercept Facilitates Vitrectomy in Proliferative Diabetic Retinopathy: Is Attention Required for the Fellow Eye?

, 2019
Purpose. To evaluate the effect of preoperative intravitreal conbercept (IVC) injection on patients with proliferative diabetic retinopathy (PDR). Methods.
Yao Yao, Jian Guo, Wei Xu, Weijing Cheng, Guoxing Xu   +4 more
core   +1 more source

Conbercept [PDF]

, 2020
openaire   +1 more source

SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

, 2017
Objective: To investigate the serum levels of vascular endothelial growth factor (VEGF) before and after intravitreal injection of conbercept or ranibizumab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy patients.
Ding, Xue, Jin, Enzhong, Zhao, Mingwei, Bai, Yujing, Luo, Ling, Qi, Huijun, Zhu, Xuemei, Huang, Lvzhen   +7 more
core  

Combined treatment of submacular hemorrhage with low-dose subretinal recombinant tissue plasminogen activator and intravitreal conbercept

Background Pars Plana Vitrectomy (PPV) combined with subretinal injection of low-dose recombinant tissue plasminogen activator (rt-PA) and intravitreal injection of Conbercept as a novel therapy for submacular hemorrhage (SMH) requires evaluation ...
Suyun Rao, Yuhe Tan, Yunxi Ma, Xufang Sun, Hao Du   +4 more
core   +1 more source

Topical Ophthalmic Liposomes Dual-Modified with Penetratin and Hyaluronic Acid for the Noninvasive Treatment of Neovascular Age-Related Macular Degeneration

International Journal of Nanomedicine
Chen Sun,1,* Shuyue Zhang,1,* Nan Xu,1,* Kun Liu,2 Fang Wei,2 Xiaoqian Zhang,1 Jigang Zhang,1 Shen Gao,3 Yuan Yu,4 Xueying Ding1 1Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,
Sun C, Zhang S, Xu N, Liu K, Wei F, Zhang X, Zhang J, Gao S, Yu Y, Ding X   +9 more
doaj  

Efficacy of conbercept pro re nata (PRN) versus treat-and-extend (T&E) regimens following five initial monthly doses in diabetic macular edema: a 24-month retrospective cohort study. [PDF]

Front Endocrinol (Lausanne)
Yang M, Jiang P, Liu Y, Wang J, Zhao X, Wang N, Tao Y, Wang H.   +7 more
europepmc   +1 more source

Systemic factors associated with poor anatomical response to anti-VEGF therapy in patients with diabetic macular edema: evidence from a large clinical cohort. [PDF]

Front Endocrinol (Lausanne)
Jia X, Shi Y, He M, Yao D, Lin C.
europepmc   +1 more source

Real-world cost evaluation of conbercept vs. ranibizumab for retinal and choroidal vascular diseases from 2021 to 2024: evidence from societal and medical insurance perspectives. [PDF]

BMC Public Health
Liu Y, Zhao J, Huang J, Qin Y, Huang Y, Fan H, Zhou W, Han H, You C, Cui Z, Belfort Junior R, Fernandes RAB, Yan H.   +12 more
europepmc   +1 more source